Clinical profile, management and outcomes in a cohort of elderly and highly comorbid patients with nonvalvular atrial fibrillation treated with rivaroxaban in routine practice

To analyze clinical profile and management of patients with nonvalvular atrial fibrillation treated with rivaroxaban in clinical practice according to age and to ascertain rates of thromboembolic and bleeding events during rivaroxaban therapy. Retrospective study of nonvalvular atrial fibrillation p...

Full description

Saved in:
Bibliographic Details
Published in:Future cardiology 2018-05, Vol.14 (3s), p.39-45
Main Authors: Guinda, David Brun, García, Óscar Callen, Pérez, Jorge Ondiviela, Aznarez, María Gracia, Bello, Pilar Artero, Fernandez, Elena Rivero, Barcos, Adolfo Marquina, Salcedo, Maite Villarroel
Format: Article
Language:English
Subjects:
Age
Anemia
Anticoagulants
atrial fibrillation
Cardiac arrhythmia
cardiology
clinical practice
Comorbidity
Drug dosages
Embolisms
Family medical history
Kidney diseases
Prevention
rivaroxaban
Stroke
Thromboembolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To analyze clinical profile and management of patients with nonvalvular atrial fibrillation treated with rivaroxaban in clinical practice according to age and to ascertain rates of thromboembolic and bleeding events during rivaroxaban therapy. Retrospective study of nonvalvular atrial fibrillation patients that started rivaroxaban therapy between May 2013 and February 2017 in the cardiology department of two hospitals from Huesca, Spain. A total of 137 patients (mean age 78.2 ± 8.9 years; CHA DS -VASc 3.5 ± 1.3; HAS-BLED 1.6 ± 0.7) were included. Comorbidity was common. After a mean duration of treatment of 30.5 ± 17.2 months, no strokes were reported. Rates of transient ischemic attack, major bleeding and intracranial bleeding were low. In this cohort of elderly and highly comorbid patients treated with rivaroxaban, rates of thromboembolic and bleeding events were low.
ISSN:1479-6678
1744-8298
DOI:10.2217/fca-2018-0025